Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06371924 |
| Other study ID # |
KCH23-156 |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
N/A
|
| First received |
|
| Last updated |
|
| Start date |
April 2024 |
| Est. completion date |
May 31, 2026 |
Study information
| Verified date |
April 2024 |
| Source |
King's College Hospital NHS Trust |
| Contact |
Alberto Sanchez-Fueyo |
| Phone |
02078485883 |
| Email |
sanchez_fueyo[@]kcl.ac.uk |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Interventional
|
Clinical Trial Summary
There are not enough donated livers for everybody who needs one, and as a result, thousands
of patients worldwide are waiting for liver transplants, with many dying while waiting for a
life-saving organ. One reason for this shortage is that some usable livers from donors who
are considered of high risk are being thrown away out of concern that they might not work
well after transplantation due to a problem called ischaemia reperfusion injury (IRI).
The discarded organs are mostly those coming from donors who have died due to cardiac arrest
(called 'donation after circulatory death' or DCD), with only 27% of them being used in the
UK. The quality of these DCD organs could be improved by changing how they are preserved
after being removed from the donor. The most commonly used strategy is still to remove the
livers and put them in an icebox ('static cold storage' or SCS). The alternative approaches,
which are more complex and expensive, but that can also improve the quality of the DCD
livers, involve using machines to pump fluids through the livers ('machine perfusion' or MP).
There are three MP methods being used in patients: 1) normothermic regional perfusion (NRP),
which involves pumping the donor's blood through the liver after the donor has died but the
liver is still in the donor's body; 2) normothermic machine perfusion (NMP), in which the
liver is pumped with blood outside of the donor's body; and 3) hypothermic machine perfusion
(HOPE), which is also used outside of the donor's body by pumping cold fluid into the liver.
HOPE and NRP have been shown to improve how well DCD livers function after transplantation.
NMP can also improve the quality of the DCD livers, but its main advantage is that it allows
confirming that the donated liver functions well before proceeding with the transplant. Until
now, there has not been a proper comparison of these methods, and the doctors do not
understand well the mechanisms through which MP improves the quality of the DCD livers.
The iInvestigators plan to conduct a study where 36 DCD human livers will be split into three
groups: SCS, NRP, and HOPE. After that, they will be put in NMP to confirm that they are good
enough to be transplanted and to study the mechanisms through which NRP, SCS and HOPE work.
Description:
Liver transplant numbers do not meet the existing needs, thousands of patients remain on
transplant waiting lists worldwide and many die while awaiting a life-saving organ. A key
contributor to organ shortage is the discarding of viable organs coming from donors
considered high-risk, for fear that they might malfunction after transplantation as a result
of a phenomenon called ischaemia reperfusion injury (IRI). Most of the discarded livers are
those donated after circulatory death (DCD), only 27% of which are currently utilised in the
UK. The quality of DCD organs can be improved by replacing the icebox (static cold storage or
SCS), which remains the main approach to preserve the livers after having been retrieved, by
strategies that perfuse the livers in a machine (machine perfusion or MP). There are
currently 3 MP strategies employed in the clinic: normothermic regional perfusion (NRP) is
used in the donors by perfusing the liver with the donor's blood at 37 degrees Celsius, and
normothermic (NMP) or hypothermic (HOPE) perfusion are used in the procured livers out of the
body (using warm or cold perfusion fluids, respectively). To date, no controlled objective
comparisons of these different MP strategies have been undertaken and doctors do not have a
good understanding of their mechanisms of action. The investigators hypothesise that the
benefits of MP will depend on the capacity of these strategies to improve the damage to the
liver cell mitochondria, which constitutes the first event that elicits IRI at the time of
transplantation. To determine this, the investigators propose to conduct a randomised
clinical trial in which 36 DCD human livers will be allocated to 1 of 3 treatment arms: i)
SCS; ii) NRP; and iii) HOPE. This will be followed by a period of time in NMP in order to
study the IRI response and determine if the quality of the livers is good enough to proceed
to transplantation. Following transplantation, patients will be followed for up to 12 months.
Our proposal will include three key objectives:
1. To investigate the role of mitochondrial damage in the IRI that takes place when DCD
livers are transplanted.
2. To determine the mechanisms through which the different MP strategies influence IRI in
DCD liver transplantation.
3. To develop markers to assess the quality of the livers while they are being perfused
using NMP before being transplanted into patients.
Our study will allow us to decipher the mechanisms of liver IRI in humans in a much better
way than what has been achieved to date. Furthermore, it will provide guidelines as to the
best way of employing the MP technologies and may result in the identification of new
treatments. Ultimately, our proposal will serve to improve the quality of DCD livers and
increase the number of patients who can safely receive a liver transplant.
